Amgen Initiates Phase I Clinical Trial of AMG133, a First-in-Class Dual GIPR Antagonist/GLP-1R Agonist, for Obesity in China

February 21, 2024, the Drug Clinical Trial Registration and Information Disclosure Platform shows that Amgen has registered a study evaluatingAMG133An Open-Label, Randomized, Parallel-Group, Single-Dose Phase I Study of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Administration (CTR20240555).

The study plans to enroll 20 subjects, randomly assigned in a 1:1 ratio to receive a single subcutaneous dose of AMG133 at 280mg or 420mg. The primary endpoint isCmax、AUClast and AUCinf, secondary endpoints include treatment-emergent adverse events, serious adverse events, and the incidence of anti-AMG 133 antibody formation.

Amgen is committed to benefiting patients worldwide who suffer from serious diseases by unlocking the potential of biology. To realize this vision, Amgen has long focused on the exploration, research and development, production, and sales of innovative human therapeutics. By leveraging advanced tools such as cutting-edge human genetics, Amgen strives to unravel the complexity of diseases and gain insights into the fundamental mechanisms of human biology.

Amgen focuses on disease areas with significant medical needs that are far from being met, leveraging its advanced experience in biopharmaceuticals to make outstanding contributions to improving human health and quality of life. Since its founding in 1980, Amgen has become one of the world's leading independent biotechnology companies, providing innovative drugs to millions of patients worldwide while also having a number of highly promising drugs in development.